Fig. 1 · Structure

Documents & Downloads

Birinapant (TL32711)

Cat. No. A12738 CAS 1260251-31-7

XIAP/cIAP1 antagonist

Birinapant, also known as TL32711, is a synthetic small molecule and peptido mimetic of second mitochondrial-derived activator of caspases (SMAC) and inhibitor of IAP (Inhibitor of Apoptosis Protein) family proteins, with potential antineoplastic activity.

In Stock

Publications for Birinapant

1 publication citing this product

  1. Antonella Antignani, .et al. , FASEB J, 2023, Dec;37(12):e23292 PMID: 37971407

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

In ALL PDX-derived cells, birinapant depleted cIAP1/2 in both sensitive and resistant models. Caspase-3/8 processing increased in sensitive models, showing that cIAP depletion alone did not establish susceptibility. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
cIAP1 (Cell-free assay) Kd <1 nM
XIAP (Cell-free assay) Kd 45 nM

Cellular Effect

Cell Line Activity Value Description Reference
MDA-MB-231 IC50 10 nM Cytotoxicity against cIAP/XIAP-dependent human MDA-MB-231 cells assessed as cell viability after 72 hrs by MTS assay [PMID: 25584393]

In Vitro Studies

Birinapant induced apoptosis in primary bulk and CD34+CD38− AML cells. Normal CD34+ cells showed substantially less apoptosis at matched tested exposures; this ex vivo comparison does not establish systemic safety. [2]

cIAP depletion and caspase processing in sensitive and resistant ALL cells

Cell-based study · Ex vivo PDX cells: sensitive Ph-like BCP-ALL PAKRSL, PALLSD, PAMDRM; resistant Ph+ BCP-ALL ALL-4 and ALL-55. [1]

Both sensitive and resistant models lost cIAP1/2 after treatment. Cleaved caspase-3 and caspase-8 increased in sensitive models by 6 h but not comparably in resistant models, placing the observed resistance downstream of cIAP depletion. This is a cellular protein response, not a binding-affinity assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
cIAP1 and cIAP2 protein levelsQualitative immunoblot response Rapid depletion within 30 min in 3 sensitive and 2 resistant PDXs.[1]
Cleaved caspase-3 and caspase-8Qualitative immunoblot response Marked increase within 6 h in sensitive PDXs, unlike resistant PDXs.[1]

Literature-Reported Treatment Conditions

Treatment concentration
1 μM
Exposure duration
0, 0.5 and 6 h
Method
Immunoblotting of total/cleaved caspases, IAPs and RIP1, with actin loading control.
Reported limits
Treatment vehicle and independent replicate count for panel F are not specified in the adopted main-text locations; caption replication statements for panels A/E must not be assigned to F.
Methods and source locations

Compound reported in the paper: Birinapant; Compound label in the paper: birinapant (SMAC mimetic)

Evidence concerns the reported birinapant material, not an Adooq lot. No salt conversion, purity equivalence or independent stereochemical validation is inferred.

Figure 1F and caption; Methods, Protein expression analysis; associated Results

cIAP1 and cIAP2 protein levels: Immunoblot time course, with 0 h baseline and actin loading control. — Figure 1F; Results, paragraph beginning Both cIAP1 and cIAP2; Methods, Protein expression analysis

Cleaved caspase-3 and caspase-8: Immunoblots compared across sensitive/resistant models and time points; no densitometric percentage inferred. — Figure 1F and accompanying Results

Primary AML apoptosis and normal CD34+ cell comparison

Cell-based study · Primary AML mononuclear cells, bulk and CD34+CD38− subsets; normal bone-marrow CD34+ cells. Figure 3A: n=7; 3B: bulk n=7 and stem/progenitor n=5; 3C: n=6; 3D: AML n=6, normal n=4. [2]

Birinapant induced concentration-dependent apoptosis in bulk and stem/progenitor AML cells. At the tested exposures, normal CD34+ cells showed substantially less apoptosis than AML CD34+ cells, including under MSC coculture and/or hypoxia. This comparison does not establish systemic safety.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Apoptosis in bulk and CD34+CD38− AML cellsQualitative concentration/time response Increasing apoptosis with birinapant concentration; activity retained with MSC coculture and/or 1% O2.[2]
Apoptosis in AML versus normal CD34+ cellsQualitative selectivity comparison Normal CD34+ cells showed substantially lower apoptosis than AML CD34+ cells at matched tested concentrations and 48 h.[2]

Literature-Reported Treatment Conditions

Treatment concentration
0, 50, 100, 200, 400 and 800 nM
Exposure duration
24 and 48 h in Figure 3A; 48 h in Figure 3B–D
Method
Annexin V flow cytometry; Figure 3C/D compare standard conditions, MSC coculture, 1% O2, and MSC coculture at 1% O2.
Reported limits
Treatment vehicle and the SI formula for specific apoptosis were not retrieved; no exact effect percentage, IC50 or complete absence of toxicity is inferred.
Methods and source locations

Compound reported in the paper: Birinapant; Compound label in the paper: birinapant (SMAC mimetic)

Evidence concerns the reported birinapant material, not an Adooq lot. No salt conversion, purity equivalence or independent stereochemical validation is inferred.

Figure 3A–D and caption; Methods, Cells, Cell Culture, and Treatments; Cell Viability Assay; Results, Examining Birinapant-Induced Apoptosis in Primary AML Cells

Apoptosis in bulk and CD34+CD38− AML cells: Annexin V assay; Figure 3 reports mean ± SD. Dose points read from axis labels, not curve interpolation. — Figure 3A–C and caption; Methods, Cell Viability Assay and Statistical Analyses

Apoptosis in AML versus normal CD34+ cells: Figure 3D: normal n=4, AML n=6; mean ± SD; no numerical percentage estimated. — Figure 3D and caption; Results, Examining Birinapant-Induced Apoptosis in Primary AML Cells

In Vivo Studies

Birinapant monotherapy significantly delayed leukemia progression in 17 of 19 pediatric ALL xenograft models. Two models showed no significant EFS difference from vehicle, underscoring model-dependent activity. [1]

In a Molm13 AML xenograft, median survival was 18 days with vehicle, 22 with birinapant, 26 with 5-azacytidine, and 30 with sequential 5-azacytidine followed by birinapant. The combination benefit cannot be assigned to birinapant alone. [2]

Single-agent activity across pediatric ALL xenografts

Animal study · NOD/SCID or NSG mice carrying 19 pediatric ALL PDXs, including 6 Ph-like PDXs; Methods specify female mice, 6–8 weeks, 20–25 g. [1]

Birinapant delayed leukemia progression in most tested models relative to vehicle, while two models lacked a significant EFS difference. Responses varied substantially by model; these mouse findings do not establish clinical efficacy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Leukemia progression delay relative to vehicleModels with significant progression delay 17/19 PDXs[1]

Conditions shared by the study groups

Vehicle
Composition not specified in retrieved main text.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle controlComparator for birinapantUntreated progression shown as dashed lines in representative models.[1]
Birinapant monotherapy
30 mg/kg
Vehicle-treated miceSignificant progression delay in 17/19 PDX models; ALL-4 and ALL-7 are nonsignificant in Figure 2C.[1]
Vehicle control
Model: NOD/SCID or NSG mice carrying 19 pediatric ALL PDXs, including 6 Ph-like PDXs; Methods specify female mice, 6–8 weeks, 20–25 g.
Treatment course: Matched control follow-up
Reported limits: Per-model supplemental data not retrieved; do not infer a uniform analyzed group size.
Birinapant monotherapy
Model: NOD/SCID or NSG mice carrying 19 pediatric ALL PDXs, including 6 Ph-like PDXs; Methods specify female mice, 6–8 weeks, 20–25 g.
Route: Intraperitoneal
Frequency: Every 3 days
Treatment course: 5 doses
Reported limits: Per-model supplemental data not retrieved; do not infer a uniform analyzed group size.
Methods and source locations

Compound reported in the paper: Birinapant; Compound label in the paper: birinapant (SMAC mimetic)

Evidence concerns the reported birinapant material, not an Adooq lot. No salt conversion, purity equivalence or independent stereochemical validation is inferred.

Figure 2A–C and caption; Results, The sensitivity of BCP-ALL to birinapant is replicated in vivo; Methods, In vivo drug treatments and Determination of in vivo treatment response

Leukemia progression delay relative to vehicle: EFS event: peripheral-blood huCD45+ cells reached 25%, or humane endpoint with leukemia-related morbidity; Methods specify two-tailed exact log-rank comparison, P ≤ 0.05. Figure 2C identifies 2 nonsignificant models. — Results, The sensitivity of BCP-ALL to birinapant is replicated in vivo, first paragraph; Figure 2A–C; Methods, Determination of in vivo treatment response and Statistical analysis

Vehicle control · Figure 2A–C; Methods, In vivo drug treatments; Results, The sensitivity of BCP-ALL to birinapant is replicated in vivo

Birinapant monotherapy · Figure 2A–C; Methods, In vivo drug treatments; Results, The sensitivity of BCP-ALL to birinapant is replicated in vivo

Birinapant and sequential 5-azacytidine in an AML xenograft

Animal study · Molm13-GFP/Luc human AML xenografts in 8–12-week-old NSG mice; n=10 initially per group, with 7 or 8 mice per group used for survival after tissue collections. [2]

Median survival was 18 days for vehicle, 22 days for birinapant, 26 days for 5-azacytidine, and 30 days for the sequential combination. The partner drug was active alone; the combination result must not be attributed to birinapant monotherapy.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Mouse survivalMedian survival Vehicle 18 days; birinapant 22 days; 5-Aza 26 days; 5-Aza followed by birinapant 30 days.[2]

Conditions shared by the study groups

Route
Intraperitoneal
Vehicle
Phosphate-buffered saline/50 mM citrate, pH 5.0
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Vehicle controlVehicle; combination also compared with both single agents.Median survival 18 days.[2]
Birinapant monotherapy
15 mg/kg
Vehicle; combination also compared with both single agents.Median survival 22 days.[2]
5-azacytidine monotherapy
5 mg/kg
Vehicle; combination also compared with both single agents.Median survival 26 days.[2]
Sequential 5-azacytidine then birinapant
5-Aza 5 mg/kg, followed by birinapant 15 mg/kg
Vehicle; combination also compared with both single agents.Median survival 30 days.[2]
Vehicle control
Model: Molm13-GFP/Luc human AML xenografts in 8–12-week-old NSG mice; n=10 initially per group, with 7 or 8 mice per group used for survival after tissue collections.
Treatment course: Control follow-up
Reported limits: Initially n=10/group; survival reported for 7 or 8/group after tissue collections, exact arm-specific n not stated.
Birinapant monotherapy
Model: Molm13-GFP/Luc human AML xenografts in 8–12-week-old NSG mice; n=10 initially per group, with 7 or 8 mice per group used for survival after tissue collections.
Frequency: Twice weekly
Treatment course: 4 weeks; begins day 3 after inoculation
Reported limits: Initially n=10/group; survival reported for 7 or 8/group after tissue collections, exact arm-specific n not stated.
5-azacytidine monotherapy
Model: Molm13-GFP/Luc human AML xenografts in 8–12-week-old NSG mice; n=10 initially per group, with 7 or 8 mice per group used for survival after tissue collections.
Frequency: Daily
Treatment course: 5 days; begins day 3 after inoculation
Reported limits: Initially n=10/group; survival reported for 7 or 8/group after tissue collections, exact arm-specific n not stated.
Sequential 5-azacytidine then birinapant
Model: Molm13-GFP/Luc human AML xenografts in 8–12-week-old NSG mice; n=10 initially per group, with 7 or 8 mice per group used for survival after tissue collections.
Frequency: 5-Aza daily; then birinapant twice weekly
Treatment course: 5-Aza for 5 days, then birinapant for 4 weeks
Reported limits: Initially n=10/group; survival reported for 7 or 8/group after tissue collections, exact arm-specific n not stated.
Methods and source locations

Compound reported in the paper: Birinapant; Compound label in the paper: birinapant (SMAC mimetic)

Evidence concerns the reported birinapant material, not an Adooq lot. No salt conversion, purity equivalence or independent stereochemical validation is inferred.

Figure 6D and caption; Methods, Xenograft Studies in NOD/SCID IL2Rγ Null (NSG) Mice; associated Results

Mouse survival: Reported values printed in Figure 6D and Results, not estimated from Kaplan–Meier curves. Methods specify log-rank survival analysis. — Figure 6D; Results, Assessment of Birinapant Alone or Combined With 5-Aza in a Xenograft Mouse Model of Human AML; Methods, Xenograft Studies

Vehicle control · Figure 6D and regimen diagram; Methods, Xenograft Studies; associated Results

Birinapant monotherapy · Figure 6D and regimen diagram; Methods, Xenograft Studies; associated Results

5-azacytidine monotherapy · Figure 6D and regimen diagram; Methods, Xenograft Studies; associated Results

Sequential 5-azacytidine then birinapant · Figure 6D and regimen diagram; Methods, Xenograft Studies; associated Results

Specifications

Manufacturer Adooq Bioscience
Actions Activator
CAS Number 1260251-31-7
Applications XIAP/cIAP1 antagonist
Formula C42H56F2N8O6
Molecular Weight 806.94
Synonyms TL-32711
SMILES
CC[C@@H](C(=O)N1C[C@H](C[C@H]1CC2=C(NC3=C2C=CC(=C3)F)C4=C(C5=C(N4)C=C(C=C5)F)C[C@@H]6C[C@@H](CN6C(=O)[C@H](CC)NC(=O)[C@H](C)NC)O)O)NC(=O)[C@H](C)NC

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 87 mg/mL (107.81 mM)
Water Insoluble
Ethanol 48 mg/mL (59.48 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Richmond J, Robbins A, Evans K, et al. Acute Sensitivity of Ph-like Acute Lymphoblastic Leukemia to the SMAC-Mimetic Birinapant Cancer research (2016). PMID: 27302164 DOI: 10.1158/0008-5472.can-16-0523 Source material
  2. [2] Carter BZ, Mak PY, Mak DH, et al. Synergistic targeting of AML stem/progenitor cells with IAP antagonist birinapant and demethylating agents Journal of the National Cancer Institute (2014). PMID: 24526787 DOI: 10.1093/jnci/djt440 Source material

Publications

1 publication citing this product

  1. Antonella Antignani, .et al. , FASEB J, 2023, Dec;37(12):e23292 PMID: 37971407

Added to your cart

View Cart Checkout
Loading...